[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611732":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":31,"locations":36,"responsibleParty":50,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":19,"overallStatus":38,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Hebei Senlang Biotechnology Inc., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"S1904 CD19 CAR-T","EXPERIMENTAL","Autologous CD19-targeting CAR T cells, dosage 1\\*10\\^6\u002Fkg, intravenous injection once",[13],"Biological: S1904 CD19 CAR-T",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Autologous CD19-targeting CAR T cells",[9],null,[21,25,28],{"name":22,"affiliation":23,"role":24},"Xiaojun Huang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":27,"role":24},"Hongsheng Zhou","Nanfang Hospital, Southern Medical University",{"name":29,"affiliation":30,"role":24},"Ruidong Zhang","Beijing Children's Hospital",[32],{"name":22,"role":33,"phone":34,"phoneExt":19,"email":35},"CONTACT","010-88325229","xjhrm@medmail.com.cn",[37],{"facility":23,"status":38,"city":39,"state":19,"zip":19,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":22,"role":33,"phone":19,"phoneExt":19,"email":19},{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100611732","phase-2-assessment-of-senlb19-car-t-cells-in-relapsedrefractory-cd19-b-all-100611732",false,"NCT07244406","Assessment of Senl_B19 CAR-T Cells in Relapsed\u002FRefractory CD19+ B-ALL","A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Senl_B19 Autologous Anti-CD19 CAR-T Cells in Subjects With Relapsed or Refractory CD19-Positive B-Cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* 1.Sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the study as stipulated in the trial flow chart; 2.Male or female subjects. Age between 3 and 25 years (inclusive) at the time of ICF signing； 3.Confirmed diagnosis of relapsed\u002Frefractory B-ALL at ICF signing; 4.\\>5% blasts on screening bone marrow biopsy\u002Faspirate; 5.CD19+ malignant cells by flow cytometry (bone marrow or peripheral blood) at screening; 6.Patients with Ph+ ALL are eligible if they meet the relapsed\u002Frefractory criteria and have either: failed ≥2 TKI regimens (unless they have a T315I mutation), demonstrated TKI intolerance, or have a contraindication to TKIs; 7.Estimated survival time\\>3 months.\n\nExclusion Criteria:\n\n* 1.Relapse of isolated extramedullary disease; 2.Burkitt lymphoma\u002Fleukemia； 3.Active acute or moderate-to-severe chronic GVHD within 4 weeks prior to ICF signing. Or, any systemic GVHD treatment within 4 weeks prior to infusion; 4.No uncontrolled active infection at the time of ICF signing or apheresis.; 5.Prior receipt of any CAR-T therapy or other cellular\u002Fgene therapy before screening; 6.Received investigational drugs or systemic anti-tumor therapy within 4 weeks or 5 half-lives (whichever longer) prior to apheresis; 7.Active interstitial lung disease\u002Fpneumonitis at the time of ICF signing; 8.Subjects whom the Investigator considers unable to comply with the study protocol or who are otherwise not an appropriate candidate for the study for any reason;","ALL","3 Years","25 Years",{"count":63,"type":64},59,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.",[70],"B-ALL","2025-11-17",{"date":73,"type":74},"2025-11-24","ACTUAL",{"date":76,"type":74},"2025-01-10",{"date":78,"type":64},"2028-12-31",{"name":5,"class":6},1]